Synthesis and Thermal Stability of Oligodeoxynucleotides
A R T I C L E S
1 H, J ) 5.0 Hz), 4.38 (dddd, 1 H, J ) 4.7, 6.3, 5.3, 2.8 Hz), 3.92
(ddd, 1 H, J ) 2.8, 4.7, 4.8 Hz), 3.46 (ddd, 1 H, J ) 5.0, 4.7, 11.8
Hz), 3.39 (ddd, 1 H, J ) 5.0, 4.8, 11.8 Hz), 2.80 (ddd, 1 H, J ) 6.0,
13.2, 6.3 Hz), 2.40 (ddd, 1 H, J ) 5.7, 13.2, 5.3 Hz); 13C NMR (DMSO-
d6) δ: 158.4, 139.0, 132.0, 129.3, 88.2, 84.9, 69.9, 61.0, 38.4. Anal.
Calcd. for C13H13N5O5: C, 48.91; H, 4.10; N, 21.93. Found: C, 48.86;
H, 4.15; N, 21.88.
(ddd, 1 H, J ) 8.1, 12.8, 5.2 Hz), 1.10-1.05 (m, 42 H); 13C NMR
(CDCl3) δ: 163.05, 149.79, 137.79, 88.81, 88.68, 83.29, 81.67, 76.86,
72.36, 63.14, 43.38, 27.84. 27.50, 17.79, 11.88, 11.66.
Methyl 1-(2-Deoxy-3,5-di-O-triisopropylsilyl-â-D-ribofuranosyl)-
5-iodoimidazole-4-carboxylate (19). To a solution of 18 (4.2 g, 4.86
mmol) in MeOH (70 mL) was added 28% NaOMe (2 mL, 9.8 mmol),
and the whole mixture was stirred at room temperature for 3 h. The
reaction was quenched by addition of saturated aqueous NH4Cl, and
the solvent was removed in vacuo. The residue was partitioned between
AcOEt and H2O. The separated organic layer was washed with H2O,
followed by brine. The organic layer was dried (Na2SO4), and
concentrated in vacuo. The residue was purified by a silica gel column
and eluted with hexane/AcOEt (9:1-2:1), to give 19 (3.24 g, 98%,
crystallized from hexane): mp 90-91 °C; FAB-LRMS m/z 681 (MH+);
1H NMR (CDCl3) δ: 8.10 (s, 1 H), 6.14 (dd, 1 H, J ) 5.5, 7.9 Hz),
4.69 (ddd, 1 H, J ) 2.4, 5.2, 1.6 Hz), 4.11 (m, 1 H), 3.92 (m, 2 H),
2.50 (ddd, 1 H, J ) 5.5, 12.9, 2.4 Hz), 2.22 (ddd, 1 H, J ) 7.9, 12.9,
5.2 Hz), 1.10-1.05 (m, 42 H); 13C NMR (CDCl3) δ: 162.75, 138.58,
135.65, 89.11, 88.93, 76.43, 72.72, 63.38, 51.77, 43.54, 17.95, 12.06,
11.84. Anal. Calcd. for C28H53IN2O5Si2: C, 49.40; H, 7.85; N, 4.11.
Found: C, 49.19; H, 7.82; N, 4.04.
5-[4-Methoxypyrimidin-2(1H)-on-5-yl]-1-(2-deoxy-3,5-di-O-triiso-
propylsilyl-â-D-ribofuranosyl)imidazole-4-carbonitrile (16). In the
similar manner as described for 14, 12 (1.68 g, 2.61 mmol) was treated
with isoamyl nitrite (3.5 mL, 26.1 mmol) to give 16 (967 mg, 57% as
a white foam): FAB-LRMS m/z 646 (MH+); 1H NMR (CDCl3) δ:
12.31 (br s, 1 H), 8.01 and 7.79 (each s, each 1 H), 5.70 (dd, 1 H, J )
7.8, 5.7 Hz), 4.72 (dt, 1 H, J ) 5.4, 2.3 Hz), 4.03 (m, 4 H,), 3.87 (m,
2 H), 2.44 (ddd, 1 H, J ) 7.8, 12.8, 5.4 Hz), 2.36 (ddd, 1 H, J ) 5.7,
12.8, 2.3 Hz), 1.08-1.04 (m, 42 H); 13C NMR (CDCl3) δ: 169.85,
158.92, 146.90, 137.74, 131.84, 115.11, 114.52, 95.77, 89.18, 85.99,
72.79, 63.64, 55.38, 43.47, 18.19, 18.15, 12.26, 12.10. Anal. Calcd.
for C32H55N5O5Si2: C, 59.50; H, 8.58; N, 10.84. Found: C, 59.72; H,
8.66; N, 10.68.
4-Amino-1-(2-deoxy-3,5-di-O-triisopropylsilyl-â-D-ribofuranosyl)-
imidazo[5′,4′:4,5]pyrido[2,3-d]pyrimidin-7(6H)-one (17). In the
similar manner as described for 15, 16 (960 mg, 1.49 mmol) was treated
with methanolic ammonia (saturated at 0 °C, 40 mL) to give 17 (882
mg, 94%, crystallized from acetone-CHCl3): mp 287-289 °C; FAB-
LRMS m/z 631 (MH+); 1H NMR (CDCl3) δ: 13.77 (br s, 1 H), 10.30
and 6.44 (each br s, each 1 H), 9.33 (s, 1 H), 8.02 (s, 1 H), 6.42 (dd,
1 H, J ) 7.9, 5.2 Hz), 4.82 (ddd, 1 H, J ) 5.0, 2.8, 1.6 Hz), 4.22 (ddd,
1 H, J ) 1.6, 2.6, 3.7 Hz), 3.88 (dd, 1 H, J ) 2.6, 11.3 Hz), 3.83 (dd,
1 H, J ) 3.7, 11.3 Hz), 2.70 (ddd, 1 H, J ) 7.9, 12.7, 5.0 Hz), 2.62
(ddd, 1 H, J ) 5.2, 12.7, 2.8 Hz), 1.12-0.99 (m, 42 H); 13C NMR
(CDCl3) δ: 160.38, 159.06, 157.45, 153.53, 137.92, 133.40, 125.15,
96.31, 89.07, 85.95, 72.35, 63.15, 40.99, 18.00, 17.86, 12.10, 11.81.
Anal. Calcd. for C31H54N6O4Si2: C, 59.01; H, 8.63; N, 13.32. Found:
C, 58.92; H, 8.56; N, 13.30.
7-Amino-1-(2-deoxy-3,5-di-O-triisopropylsilyl-â-D-ribofuranosyl)-
imidazo[5′,4′:4,5]pyrido[2,3-d]pyrimidin-4(5H)-one (22). In the simi-
lar manner as described for 11, a mixture of 19 (3.38 g, 4.97 mmol)
and 7 (3.12 g, 7.46 mmol) was treated with dba3Pd2‚CHCl3 (414 mg,
0.40 mmol) to give a brown syrup. The resulting crude mixture was
then dissolved in 1,4-dioxane (30 mL), and NH4OH (28%, 30 mL)
was added to the mixture. The whole was heated at 100 °C for 60 h in
a steel container. The solvent was removed in vacuo, and the residue
was partitioned between CHCl3 and H2O. The separated organic layer
was washed with H2O, followed by brine. The organic layer was dried
(Na2SO4) and concentrated in vacuo. The residue was purified by a
silica gel column and eluted with 0-5% EtOH in CHCl3, to give 22
(1.78 g, 57%, crystallized from acetone-CHCl3): mp 187-188 °C; FAB-
1
LRMS m/z 631 (MH+); H NMR (CDCl3) δ: 12.90 (br s, 1 H), 9.05
(s, 1 H), 7.96 (s, 1 H), 6.41 (dd, 1 H, J ) 7.7, 5.2 Hz), 4.82 (ddd, 1 H,
J ) 5.1, 2.9, 1.0 Hz), 4.20 (ddd, 1 H, J ) 1.0, 2.9, 4.0 Hz), 3.86 (dd,
1 H, J ) 2.9, 11.2 Hz), 3.80 (dd, 1 H, J ) 4.0, 11.2 Hz), 2.73 (ddd, 1
H, J ) 7.7, 12.4, 5.1 Hz), 2.63 (ddd, 1 H, J ) 5.2, 12.4, 2.9 Hz),
1.12-0.98 (m, 42 H); 13C NMR (CDCl3) δ: 162.18, 160.13, 154.56,
154.44, 137.93, 133.88, 129.81, 98.03, 89.09, 85.79, 72.48, 63.29, 40.76,
18.05, 17.90, 12.15, 11.85. Anal. Calcd. for C31H54N6O4Si2: C, 59.01;
H, 8.63; N, 13.32. Found: C, 59.06; H, 8.59; N, 13.24.
4-Amino-1-(2-deoxy-â-D-ribofuranosyl)imidazo[5′,4′:4,5]pyrido-
[2,3-d]pyrimidin-7(6H)-one (3). In the similar manner as described
for 2, 17 (220 mg, 0.35 mmol) was treated with TBAF (1 M, 0.88 mL,
0.88 mmol) to give 3 (83 mg, 74% as a white powder): FAB-LRMS
m/z 319 (MH+); UV λmax (H2O) 348 nm (ꢀ ) 17 900), 252 nm (ꢀ )
24 000); λmax (0.5 N HCl) 356 nm (ꢀ ) 17 400), 304 nm (ꢀ ) 8300),
244 nm (ꢀ ) 18 700); λmax (0.5 N NaOH) 344 nm (ꢀ ) 12 600), 252
1
nm (ꢀ ) 29 700); H NMR (DMSO-d6) δ: 11.74 (br s, 1 H), 9.09 (s,
7-Amino-1-(2-deoxy-â-D-ribofuranosyl)imidazo[5′,4′:4,5]pyrido-
[2,3-d]pyrimidin-4(5H)-one (4). In the similar manner as described
for 2, 22 (255 mg, 0.40 mmol) was treated with TBAF (1 M, 1.0 mL,
1.0 mmol) to give 4 (103 mg, 81% as a white powder): FAB-LRMS
m/z 319 (MH+); UV λmax (H2O) 333 nm (ꢀ ) 14 400), 281 nm (ꢀ )
10 900), 240 nm (ꢀ ) 28 700); λmax (0.5 N HCl) 330 nm (ꢀ ) 8500),
244 nm (ꢀ ) 33 300); λmax (0.5 N NaOH) 337 nm (ꢀ ) 13 900), 257
1 H), 8.39 (s, 1 H), 7.78 (br s, 2 H), 6.52 (dd, 1 H, J ) 6.1, 6.0 Hz),
5.37 (d, 1 H, J ) 4.5 Hz), 4.85 (t, 1 H, J ) 4.9 Hz), 4.39 (dddd, 1 H,
J ) 4.5, 6.6, 5.0, 3.4 Hz), 3.95 (ddd, 1 H, J ) 3.4, 4.0, 4.8 Hz), 3.51
(ddd, 1 H, J ) 4.9, 4.0, 11.8 Hz), 3.46 (ddd, 1 H, J ) 4.9, 4.8, 11.8
Hz), 2.75 (ddd, 1 H, J ) 6.1, 13.2, 6.6 Hz), 2.48 (ddd, 1 H, J ) 6.0,
13.2, 5.0 Hz); 13C NMR (DMSO-d6) δ: 159.5, 156.8, 156.3, 152.8,
138.8, 133.0, 123.9, 94.7, 87.9, 85.4, 69.9, 61.0. Anal. Calcd. for
C13H14N6O4‚1/3H2O: C, 48.15; H, 4.56; N, 25.91. Found: C, 48.26;
H, 4.49; N, 25.67.
1
nm (ꢀ ) 26 200); H NMR (DMSO-d6) δ: 11.52 (br s, 1 H), 8.85 (s,
1 H), 8.30 (s, 1 H), 6.89 (br s, 2 H), 6.47 (t, 1 H, J ) 6.0 Hz), 5.37 (d,
1 H, J ) 5.0 Hz), 4.86 (t, 1 H, J ) 5.0 Hz), 4.38 (dddd, 1 H, J ) 5.0,
6.3, 4.7, 3.4 Hz), 3.93 (ddd, 1 H, J ) 3.4, 4.3, 4.4 Hz), 3.51 (ddd, 1 H,
J ) 5.0, 4.3, 11.8 Hz), 3.45 (ddd, 1 H, J ) 5.0, 4.4, 11.8 Hz), 2.72
(ddd, 1 H, J ) 6.0, 13.2, 6.3 Hz), 2.45 (ddd, 1 H, J ) 6.0, 13.2, 4.7
Hz); 13C NMR (DMSO-d6) δ: 161.7, 158.3, 154.3, 153.3, 138.6, 132.7,
129.3, 96.9, 87.9, 85.3, 69.8, 61.0, 39.0. Anal. Calcd. for C13H14N6O4‚
3/10H2O‚1/5EtOH: C, 48.35; H, 4.78; N, 25.24. Found: C, 48.42; H,
4.73; N, 25.28.
1-(2-Deoxy-3,5-di-O-triisopropylsilyl-â-D-ribofuranosyl)-5-iodo-
imidazole-4-[N,N-di-(tert-butoxycarbonyl)]carboxamide (18). To a
solution of 6 (3.5 g, 5.26 mmol) in CH2Cl2 (60 mL) containing Et3N
(2.2 mL, 15.8 mmol) and DMAP (640 mg, 5.26 mmol) was added
di-tert-butyl dicarbonate (3.6 mL, 15.8 mmol), and the whole mixture
was stirred at room temperature. After 10 h, an additional di-tert-butyl
dicarbonate (1.8 mL, 7.9 mmol) was added to the reaction mixture.
After an additional 10 h, the solvent was removed in vacuo, and the
residue was purified by a silica gel column and eluted with hexane/
AcOEt (20:1-6:1), to give 18 (4.32 g, 95% as a colorless oil): FAB-
LRMS m/z 866 (MH+); FAB-HRMS calcd. for C37H69IN3O8Si2
Synthesis of ODNs. ODNs were synthesized on a DNA/RNA
synthesizer (Applied Biosystem Model 392) by the phosphoramidite
method.34 For the incorporation of the tricyclic nucleosides into the
ODNs, a 0.12 M solution of each tricyclic nucleoside phosphoramidite
1
866.3669, found: 866.3685. H NMR (CDCl3) δ: 8.04 (s, 1 H), 6.13
(dd, 1 H, J ) 5.4, 8.1 Hz), 4.68 (ddd, 1 H, J ) 2.3, 5.2, 2.6 Hz), 4.10
(m, 1 H), 3.91 (m, 2 H), 2.50 (ddd, 1 H, J ) 5.4, 12.8, 2.3 Hz), 2.22
(34) Beaucage, S. L.; Caruthers, M. H. Tetrahedron Lett. 1981, 22, 1859-1862.
9
J. AM. CHEM. SOC. VOL. 125, NO. 33, 2003 9981